Renal Tubular Function in Patients Receiving Anticonvulsant Therapy: A Long-Term Study
Version of Record online: 2 AUG 2005
Volume 41, Issue 11, pages 1432–1435, November 2000
How to Cite
Verrotti, A., Greco, R., Pascarella, R., Matera, V., Morgese, G. and Chiarelli, F. (2000), Renal Tubular Function in Patients Receiving Anticonvulsant Therapy: A Long-Term Study. Epilepsia, 41: 1432–1435. doi: 10.1111/j.1528-1157.2000.tb00118.x
- Issue online: 2 AUG 2005
- Version of Record online: 2 AUG 2005
- Accepted May 31, 2000
- Renal tubular function;
Summary: Purpose: The goal of the study was to evaluate the tubular renal function in children and adolescents who are undergoing monotherapy with sodium valproate (VPA), carbamazepine (CBZ), and phenobarbital (PB).
Methods: The urinary excretion of N-acetyl-β-glucosaminidase (NAG), β-galactosidase (β-Gal), alanine-amino-peptidase (AAP), and α1-microglobulin (α1M) was measured in 58 epileptic patients (29 girls and 29 boys), aged 12.6 ± 3.9 years, who were subdivided into three groups according to their therapy. Fifty healthy sex- and age-matched children served as controls. The measurements were taken before the beginning of therapy and after 6 months, 1 year, and 2 years of therapy.
Results: Before the beginning of therapy, there were no significant differences in NAG, β-Gal, AAP, and α1M values between the control group and the three groups of epileptic children. After 6 months of therapy, patients treated with VPA and CBZ showed a significant increase in the urinary excretion of NAG and β-Gal compared with baseline data and control values. After 1 and 2 years, these patients showed a persistence of the changes found after 6 months of therapy. In patients treated with PB, we did not find any significant variation in NAG, β-Gal, AAP, and α1M urinary excretion.
Conclusions: Our study demonstrates that in patients treated with VPA and CBZ, an impairment of tubular function can be present, whereas PB does not cause any significant change.